Steven Charles Nelson
Known title: Chief Commercial OfficerCIK: 0002025906
Steven Charles Nelson's purchase track record
How the stock did after each of Steven Charles Nelson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since August 19, 2024
Stock higher 6 months later
25%
3 months: 25%
Median 6-month return
-13.0%
3 months: -10.1%
Beat the S&P 500
25%
median -14.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2025 | DRIO | $21K | +24.4% | +11.8% | +7.2% |
| 11/12/2024 | DRIO | $5K | -28.0% | -16.7% | -1.6% |
| 9/5/2024 | DRIO | $21K | -4.1% | -9.3% | +4.3% |
| 8/19/2024 | DRIO | $23K | -16.1% | -24.4% | +9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DRIO | ▲ Buy | Grant | 30,000 | $0 | 9/11/2025 | View on chart |
| DRIO | ▲ Buy | Open Market | 40,000 | $21K | 8/27/2025 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 11/12/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 9/11/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 9/10/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 9/9/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 9/6/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 9/5/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/23/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/22/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/21/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/20/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/19/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction
DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction. DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.